Citron Research Exposes the Information that Congress Will Find if it Subpoenas Valeant
Courtesy of Citron Reports (originally posted Oct. 2, 2015)
Valeant's Business Model is Broken:
Stock is Too Dangerous to Own: Short Term Price Target – $125
Over the past two weeks, shares of Valeant (NYSE:VRX) took a steep decline over concerns of price gouging that was recently expressed by Presidential hopeful Senator Bernie Sanders. In his plea for a subpoena of Valeant Sen. Sanders would like to see all communication regarding the price hikes and the reasons behind them.
Look no further Senator — Citron has done the work.
Over the past two weeks, shares of Valeant took a steep decline over concerns of price gouging that was recently expressed by Presidential hopeful Senator Bernie Sanders. In his plea for a subpoena of Valeant Sen. Sanders would like to see all communication regarding the price hikes and the reasons behind them. Look no further Senator — Citron has done the work.
Investors, Politicians, and Concerned Citizens must note that Valeant raised the prices on the two key heart drugs in question the very next day after they acquired them … just to cover up for a bad quarter.
Here's the proof — all done without wasting taxpayer money on a hearing.
|
For the Rest of the Story You Won't Read Anywhere Else, Click Here |
Read also: Why a Congressional Subpoena to Valeant About Price Gouging on Drugs Should be Granted.
